ClinicalTrials.gg
CompletedNCT00649493Updated Apr 23, 2024

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

A Phase 1 interventional study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg in Healthy, sponsored by Mylan Pharmaceuticals Inc. Completed at 1 site in United States. Open to participants aged 8 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Mylan Pharmaceuticals Inc (part of Viatris Inc.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
8 Years and older
Sex
All
01

Study summary

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium 20 mg tablets to Eisai's Aciphex® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Mylan Pharmaceuticals Inc is the lead sponsor of 160 studies on the registry; 1 is open to participants now.

First submitted before Mylan Pharmaceuticals Inc became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy, adult subjects, 18 years and older
  • able to swallow medication

Exclusion criteria

Exclusion Criteria:

  • institutionalized subjects
  • history of any significant disease
  • use of any prescription or OTC medications within 14 days of start of study
  • received any products within 30 days prior to start of study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    1

    Rabeprazole Sodium Tablets 20 mg

    Drug: Rabeprazole Sodium Tablets 20 mg

  • Active comparator
    2

    Aciphex® Tablets 20 mg

    Drug: Aciphex® Tablets 20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.

    Time frame: blood collections through 24 hours

07

Study locations

1 site
  • PRACS Institute, Ltd.
    Fargo, North Dakota 58104, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2008
First posted
Apr 1, 2008
Start
May 2003
Primary completionActual
Jun 2003
CompletionActual
Jun 2003
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00649493
First posted
Apr 1, 2008
Start date
May 2003
Primary completion
Jun 2003
Completion
Jun 2003
Last update
Apr 23, 2024

Study contacts

James D Carlson, Pharm. D.
principal investigator · PRACS Institute Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion